Dexcom Inc. Stock
Dexcom Inc. Stock
Dexcom Inc. dominated the market today, gaining €1.87 (3.200%).
With 39 Buy predictions and 1 Sell predictions Dexcom Inc. is one of the favorites of our community.
As a result the target price of 79 € shows a positive potential of 30.86% compared to the current price of 60.37 € for Dexcom Inc..
For the coming years our community has positive and negative things to say abot the Dexcom Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 3.200% | -3.928% | 3.635% | -28.806% | 1.971% | -40.369% | -20.692% |
| Zimmer Holdings | -1.200% | -4.744% | -1.891% | -29.958% | -2.861% | -33.671% | -43.409% |
| Baxter International | -1.460% | -0.799% | 5.841% | -43.135% | 5.217% | -57.459% | -73.628% |
| Stryker Corp. | -0.970% | 0.065% | 2.209% | -16.935% | 3.471% | 32.535% | 55.280% |
Comments
DexCom (NASDAQ:DXCM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. They now have a $71.00 price target on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) had its price target raised by analysts at Mizuho from $75.00 to $78.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature
